pocketful logo
Cipla Ltd logo

Cipla Ltd

NSE: CIPLA BSE: 500087

₹1309.60

(-0.61%)

Tue, 05 May 2026, 01:53 am

mtf coin illustrationMTF 5x

Cipla Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    107826.86

  • Net Profit

    5291.05

  • P/B

    3.73

  • Sector P/E

    33.38

  • P/E

    22.08

  • EV/EBITDA

    14.53

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    18.28

  • ROCE

    23.15

  • Debt/Equity

    0.02

  • EPS (TTM)

    58.86

  • Dividend Yield

    1.20

  • Book Value

    407.52

  • Interest Cover

    111

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are well covered by earnings (6.4x coverage).
  • Dividends after 3 years are expected to be well covered by earnings (6.2x coverage).
  • Dividends per share have been stable in the past 10 years.
  • Cipla's earnings growth is expected to exceed the low risk savings rate of 7.2%.
thumbs up icon

Cons

  • Cipla's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Cipla's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Cipla is expected to decrease over the next 2 years.
  • Cipla's earnings are expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).
  • Cipla's earnings growth is positive but not above the India market average.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters29.2129.2129.2129.1929.20
FII22.5523.9324.5425.2426.28
DII31.9730.7230.2529.2628.15
Public16.2616.1315.9916.3016.37
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

65.66

MACD

14.77

50 DMA

1282.38

200 DMA

1446.46

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1596.571432.471371.031268.371206.931104.27940.17
Fibonacci1432.471369.781331.051268.371205.681166.951104.27
Camarilla1354.731339.681324.641268.371294.561279.511264.47

Pivots Level: Classic

R3

+328.20

1596.57

R2

+164.10

1432.47

R1

+102.67

1371.03

1268.37
1268.37
Pivot Point
LTP: 1335

S1

-61.43

1206.93

S2

-164.10

1104.27

S3

-328.20

940.17

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1294.71

  • 20-EMA

    1276.06

  • 30-EMA

    1274.80

  • 50-EMA

    1290.23

  • 100-EMA

    1341.24

  • 200-EMA

    1400.66

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
23 Jan 2026board-meetingsQuarterly Results
30 Oct 2025board-meetingsQuarterly Results
27 May 2025dividendFinal Dividend - Rs. - 1327 Jun 2025
13 May 2025agm
13 May 2025dividend₹13.00 Dividend /Share27 Jun 2025
02 Jul 2024dividendFinal Dividend - Rs. - 1302 Aug 2024
10 May 2024agm
10 May 2024dividend₹13.00 Dividend /Share02 Aug 2024
11 Jul 2023agm
21 Jun 2023dividendFinal Dividend - Rs. - 8.521 Jul 2023

Read More

Peer Comparison

Cipla Ltd logo

Cipla Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Cipla Ltd About

Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1935

Headquarters

CEO

Y K Hamied

Employees

Contact

Website icon

Website

http://www.cipla.com

Email icon

Email

cosecretary@cipla.com, contactus@cipla.com

Phone icon

Phone

91-22-24826000

Location icon

Location

Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel, Mumbai, Maharashtra, 400013

Read More

Cipla Ltd Company History

YearHistory
2020
  • Completed phase-3 clinical study of generic asthma drug.
  • Inked licensing pact with Gilead Sciences for potential COVID-19 treatment drug.
  • Launched generic remdesivir for coronavirus patients.
  • Collaborated with Stempeutics to launch Stempeucel for CLI treatment in India.
  • Launched antibody detection kit for COVID-19 in India.
  • Conferred Golden Peacock Global Award for Excellence in Corporate Governance 2020.
2021
  • Set up 30 MW solar plant in Maharashtra.
  • Partnered with Alvotech to market biosimilars in Australia and New Zealand.
  • Bagged National Energy Conservation Award 2021 in drug and pharmaceutical sector.
  • Won Gold for Remdesivir in Covid Care Brand Category.
2022
  • Launched leuprolide acetate injection depot (22.5mg).
  • Received USFDA approval for generic Revlimid (Lenalidomide Capsules).
  • Launched child-friendly 4-in-1 antiretroviral treatment for HIV with DNDi in South Africa.
  • Scored highest among pharma companies in CRISIL Sustainability Rating 2022.
  • Won Frost & Sullivan and TERI Sustainability 4.0 Award.
2023
  • Acquired additional stake in GoApptiv Private Limited.
  • Announced acquisition of South Africa-based Actor Pharma.
2024
  • Acquired additional shares in Achira Labs Private Limited.
  • Merged Cipla Technologies LLC, USA with Cipla USA Inc.
  • Announced joint venture in the US with Kemwell Biopharma and Manipal Education & Medical Group for cell therapy products.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
SAMINA HAMIEDSell89547501518.7502 Dec 2024
RUMANA HAMIEDSell49432501518.7502 Dec 2024
SAMINA HAMIEDSell8954750134515 May 2024
RUMANA HAMIEDSell4943250134515 May 2024
ICICI PRUDENTIAL MUTUAL FUNDBuy5525999134515 May 2024
SHIRIN HAMIEDSell6363000134515 May 2024
Y K HAMIEDSell13446504910.0515 Feb 2022
M K HAMIEDSell6723252910.1515 Feb 2022

Read More

Cipla Ltd News

Citigroup Sets ₹1,530 Target for Cipla Stock

Citigroup maintains Buy rating on Cipla with ₹1,530 target price amid rising generic Symbicort competition from Teva and Viatris, emphasizing need for timely US FDA approval.

28 Apr 2026

investment-ideas

Cipla Faces US$90-100mn Revenue Risk From FDA Alert

Macquarie notes FDA import alert on Pharmathen's Greece plant blocks Lanreotide supplies to US, putting US$90-100mn revenue at risk with FY27 restart hopes now unlikely.

24 Apr 2026

companies

Cipla Lanreotide Injection Revenue Projections

Analysts project Cipla's Lanreotide injection manufacturing unit to generate $50-60 million revenue in FY27, potentially reaching $100 million in FY28, marking significant growth potential.

24 Apr 2026

companies

Cipla Partner Pharmathen Facility Under FDA Alert

Cipla's partner Pharmathen International's Rodopi facility in Greece is under FDA import alert, potentially affecting the pharmaceutical company's operations and supply chain partnerships.

24 Apr 2026

companies

Cipla Gets FDA Nod for Generic Ventolin HFA

Cipla receives U.S. FDA approval for first AB-rated generic of Ventolin HFA with launch planned in H1 FY 2026-27, strengthening respiratory portfolio in $1.5 billion market.

24 Apr 2026

companies

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800